Factors associated with adherence to phosphodiesterase type 5 inhibitors for the treatment of pulmonary arterial hypertension

This study analysed pharmacy benefit claims of naive tadalafil (Adcirca) and sildenafil (Revatio) users between 1 Jan 2008 and 31 Dec 2010.  Patients were considered adherent if their proportion of days covered (PDC) was 80% or more over a 6-month period.  Logistic regressions were estimated to assess the factors associated with adherence.  Analyses were stratified by use of a specialty pharmacy or retail pharmacy.  A sensitivity analysis was performed by excluding individuals with 90-day supply. Results: Of the total of 2143 patients included, 46.8% were adherent.  Adherence was higher among 930 specialty pharmacy users (65.6%) than 1213 retail pharmacy users (32.3%, p less than 0.001).  Adherence was higher among Adcirca users (60.7%; approved dose ...
Source: NeLM - Cardiovascular Medicine - Category: Cardiology Source Type: news